f Pneumocystis pneumonia (PcP) is a significant cause of morbidity and mortality in immunocompromised patients. In humans, PcP is caused by the opportunistic fungal species Pneumocystis jirovecii. Progress in Pneumocystis research has been hampered by a lack of viable in vitro culture methods, which limits laboratory access to human-derived organisms for drug testing. Consequently, most basic drug discovery research for P. jirovecii is performed using related surrogate organisms such as Pneumocystis carinii, which is derived from immunosuppressed rodents. While these studies provide useful insights, important questions arise about interspecies variations and the relative utility of identified anti-Pneumocystis agents against human P. jirovecii. Our recent work has identified the histone acetyltransferase (HAT) Rtt109 in P. carinii (i.e., PcRtt109) as a potential therapeutic target for PcP, since Rtt109 HATs are widely conserved in fungi but are absent in humans. To further address the potential utility of this target in human disease, we now demonstrate the presence of a functional Rtt109 orthologue in the clinically relevant fungal pathogen P. jirovecii (i.e., PjRtt109). In a fashion similar to that of Pcrtt109, Pjrtt109 restores H3K56 acetylation and genotoxic resistance in rtt109-null yeast. Recombinant PjRtt109 is an active HAT in vitro, with activity comparable to that of PcRtt109 and yeast Rtt109. PjRtt109 HAT activity is also enhanced by the histone chaperone Asf1 in vitro. PjRtt109 and PcRtt109 showed similar low micromolar sensitivities to two reported small-molecule HAT inhibitors in vitro. Together, these results demonstrate that PjRtt109 is a functional Rtt109 HAT, and they support the development of anti-Pneumocystis agents directed at Rtt109-catalyzed histone acetylation as a novel therapeutic target for human PcP.
P
neumocystis pneumonia (PcP) is a significant cause of morbidity and mortality among patients with HIV infection or other immunosuppressive conditions (1) (2) (3) (4) . The incidence of PcP has risen significantly among certain non-HIV patients due to the increased use of immunosuppressive therapies related to the management of organ transplantation, autoimmune diseases, and cancer (5-7). The reported mortality rates for PcP range between 10 and 30% for AIDS patients and between 30 and 70% for selected non-HIV-infected patients with immunosuppression (8) (9) (10) (11) (12) (13) . Several factors contribute to poor PcP outcomes, including delayed diagnosis (14, 15) and complex host-pathogen interactions (16) (17) (18) (19) (20) (21) . Like other opportunistic fungal pathogens, there is also the emerging threat of Pneumocystis populations developing resistance to the currently available therapeutic agents (22) (23) (24) . In humans, PcP is caused by the opportunistic fungal species Pneumocystis jirovecii, which specifically infects human hosts and is not viable in other immunosuppressed mammalian hosts. Unfortunately, research progress has been hindered by the lack of continuous in vitro propagation methods for Pneumocystis, which limits ready access to viable organisms for laboratory research and drug discovery studies (25, 26) . As a result, most drug discovery for PcP has been performed with other species of Pneumocystis, such as Pneumocystis carinii or Pneumocystis murina generated in rats or mice, respectively (27) (28) (29) . However, questions remain regarding whether agents identified as having anti-Pneumocystis activity against P. carinii possess critical activity against the causal pathogen in human disease, namely, P. jirovecii. Validation of anti-P. jirovecii drug activity and fundamental target characterization studies represent critical steps in the process of therapeutic target validation.
In this light, we recently characterized the histone acetyltransferase (HAT) Rtt109 in P. carinii (30, 31) . Rtt109 HATs were first discovered in Saccharomyces cerevisiae because they catalyze a specific atypical posttranslational histone modification, i.e., histone H3 lysine 56 acetylation (H3K56ac) (32) (33) (34) (35) . Rtt109-catalyzed H3K56ac occurs during the S phase of the cell cycle and promotes genotoxic resistance, as it is associated with DNA replication and DNA repair (34) (35) (36) (37) . Rtt109 homologues have been found widely across the fungal kingdom, but no sequence homologies have been found in humans, making these potentially attractive targets for antifungal drug development. In humans and other mammals, H3K56ac is catalyzed by the HATs p300/CREB-binding protein (CBP) or GCN5 (38, 39) . Additional evidence indicates that deletion of rtt109 in the opportunistic fungal pathogen Candida albicans reduces fungal infection burdens in mouse models (40, 41) . On this basis, we postulate that specific inhibitors of fungal Rtt109-catalyzed histone acetylation may be useful as novel antifungal agents, with minimal mammalian toxicities, and may have activity against recalcitrant organisms such as P. jirovecii (42, 43) . Pneumocystis is challenging to treat with standard antifun-gals, and the use of the available agents can be limited by drugrelated toxicities. Accordingly, efficacious anti-Pneumocystis agents with minimal human toxicities still represent an unmet clinical need, despite significant efforts over the course of several decades (44) (45) (46) (47) (48) (49) .
In the current investigation, we show that P. jirovecii expresses a functional Rtt109 HAT (i.e., P. jirovecii Rtt109 [PjRtt109]). We confirm the location of the Pjrtt109 gene within the recently sequenced P. jirovecii genome. Using heterologous expression, we demonstrate that Pjrtt109 restores H3K56ac levels and genotoxic resistance in rtt109-null yeast. PjRtt109 protein exhibits HAT activity in vitro, and this activity is enhanced by the addition of the histone chaperone Asf1. Finally, we demonstrate that PjRtt109 enzymatic activity can be inhibited by reported small-molecule HAT inhibitors, one of which reduces the viability of Pneumocystis organisms. Both PjRtt109 and P. carinii Rtt109 (PcRtt109) were inhibited by low micromolar concentrations of these two compounds in vitro. Together, these results demonstrate that PjRtt109 is a functional Rtt109 HAT, representing an attractive target for therapeutic development targeting human PcP.
MATERIALS AND METHODS
Generation of full-length Pjrtt109 cDNA and subcloning into expression vectors. The full-length 1,143-bp Pjrtt109 cDNA was synthesized commercially (GenScript USA) and subcloned into pUC57. This plasmid containing the full-length Pjrtt109 cDNA reading frame was then used as a template in PCRs using Pfu DNA polymerase (Life Technologies). The cDNA was then cloned into the yeast pYES2.1 TOPO or pGEX-4T1 bacterial expression vector. Induction of gene expression in both bacteria and yeast has been described previously (30) .
Verification of Pjrtt109 in P. jirovecii genome. The PCR with the partial Pjrtt109 DNA sequence was conducted using standard protocols. Briefly, total genomic DNA from P. jirovecii was recovered from bronchoalveolar lavage (BAL) fluid specimens from potential positive cases of Pneumocystis pneumonia. We obtained clinical waste BAL fluid samples after all clinical diagnostic testing had been performed. We used the entire residual samples (generally Ͻ5 ml) to isolate P. jirovecii organisms, as described previously (30) . The entire P. jirovecii isolate was lysed in toto, and nucleic acids were extracted. Freshly isolated P. jirovecii genomic DNA was prepared with the IsoQuick nucleic acid extraction kit (Orca Research). After isolation, approximately 250 ng of DNA was used in a PCR utilizing Pfu DNA polymerase with the following Pjrtt109 gene-specific primers: forward, 5=-TGGTGGGCAAAAGTGTTGG-3=; reverse, 5=-GTGTCTCAAAATCAGAACGC-3=. To verify that these primers would not amplify segments of human genomic DNA, the primer set was also tested against human DNA isolated from healthy lung cells (Amsbio). Using another set of specific primers, the human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) gene was amplified to verify that this DNA supply was not degraded. The sequences for the hGAPDH primers were as follows: forward, 5=-CGGATTTGGTCGTATTGGGC-3=; reverse, 5=-TGGAAGATGGTGATGGGATTTC-3=.
Heterologous expression of Pjrtt109 in yeast. The BY4741 rtt109-null (YLL002W, MATa his3⌬0 leu2⌬0 met15⌬0 ura3⌬0 rtt109⌬) S. cerevisiae strain was transformed with either a control vector (pYES2.1/V5-His/ lacZ) or pYES2.1 TOPO containing the in-frame full-length Pjrtt109 cDNA (pYES2.1/Pjrtt109). Expression of downstream Pjrtt109 cDNA was under the control of the yeast GAL1 promoter, which can be induced with the addition of 2% galactose to the medium. The parent strain BY4741 (MATa his3⌬0 leu2⌬0 met15⌬0 ura3⌬0) with pYES2.1/V5-His/lacZ was used as the wild-type (WT) control. Cells were grown overnight at 30°C in synthetic complete medium containing 2% glucose and supplemented with appropriate amino acids but lacking uracil, to select and to maintain the plasmids. S. cerevisiae strains were then grown overnight in liquid minimal medium minus uracil and with 2% galactose in place of glucose.
Yeast whole-cell extracts were prepared using standard procedures. For genotoxic sensitivity assays, yeast extracts were serially diluted to 1 ϫ 10 6 cells/ml. We then plated 10 l of serial 10-fold dilutions of the indicated yeast strains onto solid minimal medium lacking uracil and containing 2% galactose. Alternatively, yeast extracts were plated onto solid minimal medium lacking uracil and containing 2% galactose plus one of the following DNA-damaging agents: 1 g/ml camptothecin (CPT), 50 mM hydroxyurea (HU), or 0.005% methyl methanesulfonate (MMS). Cells were grown for 72 h at 30°C and then assessed for growth by inspecting the colony diameters.
Expression and purification of recombinant proteins. Recombinant Schizosaccharomyces pombe Rtt109 (SpRtt109), PjRtt109, PcRtt109, REG␣, and glutathione S-transferase (GST) proteins were produced using standard procedures (30, 31) . Briefly, full-length cDNAs were amplified from cDNA using Pfu DNA polymerase. Genes were further cloned into the pGEX-4T1 vector, sequenced, and transformed into bacterial strain BL21(DE3)pLys-S. GST-tagged proteins were produced overnight at 18°C by induction with 0.5 mM isopropyl ␤-D-1-thiogalactopyranoside. Culture broths (typically 1 to 2 liters) were centrifuged, and cell lysates were obtained by passing the suspended pellets through a French press in lysis buffer supplemented with protease inhibitors. The resulting lysates were sonicated briefly and then centrifuged to remove insoluble debris. The proteins were collected onto glutathione-Sepharose beads (GE Healthcare), washed, and then eluted with a standard glutathione gradient. Eluted proteins were dialyzed overnight at 4°C in protein storage buffer containing 10% glycerol (vol/vol) and 1 mM dithiothreitol (DTT). SDS-PAGE, followed by Coomassie brilliant blue (CBB) staining, was used to verify gross protein purity and the correct molecular weights of the purified proteins. Drosophila histone tetramers (dH3-H4) were obtained as previously described (50) . Bovine serum albumin (BSA) (Sigma) was used as a negative protein control in some experiments.
Histone acetyltransferase assays. HAT activity was measured in vitro as previously reported, but with some minor modifications (34, 51) . Reactions were performed in triplicate at 30°C for 30 min in 30-l volumes containing final concentrations of 50 mM Tris-HCl (pH 8.0), 50 mM KCl, 0.1 mM EDTA, 1 mM DTT, 5 mM phenylmethylsulfonyl fluoride (PMSF), 5 mM sodium butyrate, 0.01% Triton X-100 (vol/vol), and approximately 2.5 M [
3 H]acetyl-coenzyme A (PerkinElmer). Enzymes were tested at approximately 800 nM concentrations, while recombinant dH3-H4 tetramers (1.25 M) were used as the acetylation substrate. Reaction mixture aliquots (15 l) were immediately spotted onto Whatman P-81 phosphocellulose paper filters (GE Healthcare) and air dried. Filter papers were washed five times (5 min per cycle) with 50 mM NaHCO 3 (pH 9.0), rinsed with acetone, and then allowed to air dry for 30 min. [ 3 H]Acetate incorporation was then measured with an LS6500 liquid scintillation counter (Beckman-Coulter). Acetylated proteins were identified by autoradiography after the resolution of reaction mixture aliquots on 15% SDS-PAGE gels. The gels were soaked in Amplify fluorographic reagent (GE Healthcare) for 30 min and then dried under vacuum for 2 h at 80°C. Films were then exposed to the gels at Ϫ80°C, typically for 48 h. The acetylation status of H3K56 was assessed by Western blotting of reaction samples as described above but using unlabeled acetyl-CoA (sodium salt, 10 M final concentration; Sigma) from stocks stored in 0.01 M sodium acetate (pH 5.0). Membranes were imaged with a LI-COR Odyssey system, and data were analyzed using Image Studio software (LI-COR Biosciences). Purified REG␣ was used as a negative enzymatic control (30) . Purified GST was included as an additional tag control.
Protein complex assays. Protein complexes were assembled using standard procedures. S. cerevisiae Asf1 (ScAsf1) was produced as described previously (52) . To obtain the ScAsf1-dH3-H4 complex, approximately equimolar amounts of ScAsf1 and dH3-H4 (as determined by SDS-PAGE separation and subsequent CBB staining) were incubated overnight at 4°C and purified by gel filtration chromatography (52) . Experiments were performed as described above, except that enzymes were tested at approx-imately 400 nM and HAT reactions were allowed to proceed for up to 30 min.
Compounds and reagents. Garcinol, a natural product with reported anti-HAT activity in vitro, was purchased as a solid powder (Enzo Life Sciences) and was used without further purification. Compound 1 (PubChem compound identification 4785700), which has recently been reported to have selective activity against yeast Rtt109 in vitro, was also obtained commercially as a solid powder (Enamine) and was used after standard reverse-phase high-performance liquid chromatography (RP-HPLC) purification (43) . All solids showed greater than 98% purity in ultra-performance liquid chromatography/mass spectrometry (UPLC/ MS) analyses, and their 1 H and 13 C NMR spectra were consistent with their reported chemical structures. Compounds were prepared as 10 mM stock solutions in dimethyl sulfoxide (DMSO) and were stored at Ϫ20°C under a vacuum seal. The 1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded on a Bruker Avance spectrometer, while the UPLC-MS analyses were performed using a Waters Acquity UPLC system equipped with a ZQ mass spectrometer, a photodiode array, and evaporative light-scattering detectors.
Anti-HAT activity dose-response analyses. Garcinol and compound 1 were tested at up to 10 concentrations (final compound concentrations of 20 nM to 250 M) using the aforementioned [
3 H]acetyl-CoA in vitro HAT assay, with some minor modifications (42) . Briefly, test compounds were allowed to preequilibrate with the enzyme (approximately 400 nM) and histone substrate for 5 min at 30°C before the HAT reaction was initiated with the addition of [
3 H]acetyl-CoA. Reactions were performed in 60-l total volumes. The DMSO content was kept constant at 3% (vol/vol), and protease inhibitors were omitted from the reaction mixtures. The HAT reactions were allowed to proceed for 10 min, after which reaction mixture aliquots were immediately spotted onto P-81 filter paper and worked up as described above. Percent inhibition was calculated as a percentage of the DMSO control value minus the background value. Dose-response curves were generated in GraphPad Prism 6.0, using the sigmoidal dose-response variable-slope four-parameter equation.
Effects of reported HAT inhibitors on Pneumocystis viability. Compound 1 and garcinol were incubated with freshly isolated P. carinii organisms maintained ex vivo in viability medium for 72 h. Relative viability was assessed by measuring the ATP contents of the organisms using an ATP bioluminescent assay, as described previously (53) . The ATP assay measures the viability of mixed isolates of Pneumocystis trophic forms and cysts. Approximately 5 ϫ 10 7 organisms were tested under each condition, in RPMI 1640 medium containing 20% fetal bovine serum to promote viability. Each compound was tested in triplicate, and a total of three independent experiments were performed using three separate isolations of P. carinii organisms. As controls, P. carinii organisms were also maintained in medium alone, in medium containing 10 g/ml ampicillin (Sigma), or in medium containing the amount of DMSO diluent required to solubilize the test agents. In addition, pentamidine isethionate (Sigma) was tested at 1 g/ml as a positive-control compound for anti-Pneumocystis activity. The organisms were incubated at 37°C with 5% CO 2 in standard 24-well plates. After 72 h, equal volumes (50 l) were removed from each well, and the ATP levels were quantified using an ATPLite-M kit (PerkinElmer).
Statistical analyses. All data are expressed as mean Ϯ standard deviation. Differences between groups were determined using one-way analysis of variance (ANOVA) and multiple-comparison tests. Graphing and statistical testing were performed using GraphPad Prism, with statistical differences considered significant at P values of Ͻ0.05, Ͻ0.01, and Ͻ0.001.
RESULTS
P. jirovecii expresses an Rtt109 gene orthologue. To address whether P. jirovecii contains a potential Rtt109 HAT, we performed an in silico search of the recently reported P. jirovecii genome (54, 55) . A putative Pjrtt109 orthologue (GenBank accession number CCJ28444) was identified in a pairwise alignment with PcRtt109 (GenBank accession number ACR39370.1), showing 61% primary sequence conservation (Fig. 1, top) . The moderate divergence between these two closely related species is not unexpected, as several features in the mitochondrial DNA of P. murina and P. carinii diverge from those of P. jirovecii (56) , and this pattern of sequence similarity has also been observed between P. carinii and P. jirovecii dihydrofolate reductases (47, 57) . In addition, there appears to be significant genetic diversity at several regions among P. jirovecii isolates, based on genetic analyses (58) (59) (60) (61) . The putative PjRtt109 sequence showed several conserved regions in comparison with other previously characterized fungal Rtt109 proteins, such as those of Saccharomyces cerevisiae (GenBank accession number Q07794), Schizosaccharomyces pombe (GenBank accession number Q9Y7Y5), and Candida albicans (GenBank accession number Q5AAJ8) (Fig. 1, bottom) . These regions included the aspartic acid at amino acid position 84 in the conserved SKAD motif. Mutations of this specific residue result in nearly complete abolishment of in vitro H3 histone acetylation at the K56 position for both PcRtt109 and S. cerevisiae Rtt109 (ScRtt109) (30, 34) . As with PcRtt109, the Pjrtt109 gene encodes a conserved lysine residue at amino acid position 221, which is analogous to the site for autoacetylation in yeast Rtt109 (62, 63) . Furthermore, P. murina Rtt109 (GenBank accession number EMR10273) showed significant homology to both PjRtt109 and PcRtt109 (data not shown).
Despite difficulties associated with studying Pneumocystis organisms in the laboratory, additional evidence supports the idea that Pjrtt109 is expressed by P. jirovecii. P. jirovecii organisms were obtained from a BAL fluid sample from a patient with PcP, and total RNA was extracted and amplified nonspecifically prior to sequencing (54) . A total of 56 RNA-sequencing reads mapped unambiguously to the putative Pjrtt109 gene (http://www.ebi.ac .uk/ena/data/view/ERP001479). Additionally, the Pjrtt109 gene was present in the transcriptome assembly (HAAA01000299) (http://www.ebi.ac.uk/ena/data/view/HAAA01000299), which was assembled de novo using RNA-sequencing reads (O. Cissé, personal communication).
With this information, we next sought to confirm the presence of the putative Pjrtt109 gene in P. jirovecii organisms in vivo. To accomplish this, we extracted P. jirovecii genomic DNA from BAL fluid samples obtained from patients with confirmed cases of PcP at the Mayo Medical Center. These Pneumocystis infections were confirmed with our recently published single-copy nonnested PCR assay that distinguishes active PcP from simple Pneumocystis colonization (64) . Primers based on the cDNA sequence of Pjrtt109 were mixed with either P. jirovecii genomic DNA or human genomic DNA isolated from healthy human lung cells. As expected, the Pjrtt109 primer set amplified a specific amplicon of the expected size with P. jirovecii genomic DNA as the template but not with human genomic DNA as the template (Fig. 2) . As a positive control for human DNA quality, we also included a primer set based on the hGAPDH gene, which amplified an expected amplicon using human genomic DNA but not P. jirovecii genomic DNA (Fig. 2) . These results strongly support the idea that P. jirovecii contains the Pjrtt109 gene and this gene is specifically represented in the P. jirovecii genome.
Pjrtt109 restores H3K56ac levels and genotoxic resistance in rtt109-null yeast. In S. cerevisiae, Rtt109 is required for H3K56ac and is associated with genotoxic resistance due to its role in replication-coupled nucleosome assembly (34) . Pneumocystis species cannot be maintained using in vitro culture methods and cannot yet be manipulated genetically. To circumvent these issues, our group assesses Pneumocystis gene function using heterologous expression and complementation in other fungi such as S. cerevisiae (65, 66) . In this manner, we evaluated the potential activities of Pjrtt109 in complementing the H3K56 acetylation defect in rtt109-null yeast by transforming this strain with either pYES2.1/ V5-His/lacZ alone or the same vector containing full-length Pjrtt109. Western blots of yeast whole-cell extracts demonstrated that rtt109-null yeast cells were unable to acetylate H3K56. In contrast, Pjrtt109 cDNA complementation efficiently restored H3K56ac levels in rtt109-null yeast to levels seen in WT yeast (Fig. 3A) .
In addition, rtt109-null yeast demonstrated increased sensitiv- ity to genotoxins such as MMS, CPT, and HU (34, 35) . As anticipated for a putative Rtt109 HAT, Pjrtt109 complementation restored genotoxin resistance in rtt109-null yeast to the level in WT yeast (Fig. 3B) ized Rtt109 enzymes (Fig. 4B) . Western blots verified that PjRtt109 catalyzed H3K56ac in vitro (Fig. 4C) . To show that PjRtt109 was homologous to fungal Rtt109 HATs outside the Pneumocystis genus, the HAT activities of Pneumocystis jirovecii Rtt109 and Schizosaccharomyces pombe Rtt109 were also compared in vitro (30, 52, 67) . The recombinant enzymes demonstrated comparable HAT activities (Fig. 4D) . Autoradiographs (Fig. 4E ) and Western blots (Fig. 4F) showed that both Rtt109 proteins catalyzed acetylation on histone H3 and both proteins were capable of acetylating H3K56 in vitro. Autoacetylation is an important regulatory element in ScRtt109 (62, 63) , and low-level autoacetylation has been observed for PcRtt109 (30) . As expected, we observed a band consistent with PjRtt109 autoacetylation using extended-exposure autoradiographs, demonstrating that autoacetylation is likely a conserved feature of Rtt109 HATs (Fig.  4G ). These results demonstrate that PjRtt109 possesses functional Rtt109 HAT activity in vitro and that this activity is comparable to that of other fungal Rtt109 HATs. Such information is vital for the eventual development of Rtt109 inhibitors with the potential for therapeutic activity across a variety of clinically relevant fungal species that infect humans, such as P. jirovecii. PjRtt109 HAT activity is enhanced by the histone chaperone Asf1 in vitro. Rtt109 is subject to complex regulation by histone chaperones both in vitro and in vivo. One such chaperone, Asf1, enhances the in vitro HAT activity of Rtt109 in both yeast and P. carinii (30, 31, 52, 68) and is required for H3K56ac in vivo (35) . The addition of recombinant ScAsf1 to dH3-H4 tetramers significantly enhanced PjRtt109-catalyzed HAT activity in vitro (Fig.  5A ). As expected, autoradiography confirmed that the enhanced acetylation was confined to histone H3 and not ScAsf1 or histone H4 (Fig. 5B) . Western blots confirmed that this ScAsf1-mediated increase in PjRtt109-catalyzed histone acetylation in vitro led to an increase in H3K56ac (Fig. 5C ). These results demonstrate that, like previously characterized Rtt109 HATs, PjRtt109 HAT activity in vitro is enhanced by the histone chaperone Asf1.
PjRtt109 HAT activity is inhibited by small molecules in vitro. Currently, there are no reports of small molecules that specifically inhibit PjRtt109 or PcRtt109 activity. In the absence of such compounds, we examined the effects of several previously reported HAT inhibitors on PjRtt109 enzymatic activity in vitro. Garcinol is a polyisoprenylated benzophenone natural product that is reported to inhibit several HATs, including p300/CBP-associated factor (PCAF) and p300, in the low micromolar range in vitro (69, 70) . We recently showed that garcinol inhibits PcRtt109 HAT activity and yeast Rtt109-Vps75 in vitro at low micromolar concentrations (31, 42) . Of note, we observed that garcinol inhibited PjRtt109 HAT activity in vitro in a dose-dependent manner (IC 50 , 2.7 Ϯ 0.72 M) (Fig. 6A and  B) . Compound 1 has been recently reported as a low-nanomolar inhibitor of yeast Rtt109 in vitro and does not inhibit the HATs p300 and GCN5 in vitro (43) . Like garcinol, compound 1 showed dosedependent inhibition of PjRtt109 HAT activity in vitro (IC 50 , 4.3 Ϯ 3.9 M) (Fig. 6A and B) . Fluconazole, an inhibitor of fungal cytochrome 14␣-demethylase with no reported activity against HATs, was used as a negative-control compound. Both garcinol and compound 1 inhibited PjRtt109 and PcRtt109 at low micromolar concentrations (Fig. 6B) . Using the reaction mixtures for garcinol, we confirmed dose-dependent decreases in histone acetylation via autoradiography (Fig. 6C) and Western blotting for both H3K56ac and H3K27ac (Fig. 6D ). These results demonstrate that PjRtt109 is capable of in vitro enzymatic inhibition by small molecules at low micromolar concentrations and that PjRtt109 and PcRtt109 are inhibited at similar compound concentrations under the conditions tested.
Effects of small-molecule inhibitors of HAT activity on Pneumocystis viability. Finally, as support of the concept, we sought to investigate whether these reported small-molecule inhibitors of HAT activity might also alter Pneumocystis viability in vivo, using a previously described ATP-based viability assay (53) . To investigate, we utilized freshly isolated P. carinii organisms, since these are readily available in the laboratory and because our prior experiments demonstrated comparable activities of the tested HAT inhibitors against PcRtt109 and PjRtt109 in vitro. Interestingly, the general HAT inhibitor garcinol demonstrated dose-dependent suppression of P. carinii viability, as measured by ATP contents (Fig. 7) . In contrast, the recently reported yeast Rtt109 inhibitor compound 1 failed to induce any reductions of P. carinii viability under the conditions tested. Pentamidine and ampicillin served as positive-and negative-control compounds, respectively. The lack of observed activity for compound 1 is consistent with its lack of activity against C. albicans in vivo (43) . However, the activity of the reported HAT inhibitor garcinol to suppress Pneumocystis viability does support the further investigation of this class of agents, as well as novel small molecules with more drug-like characteristics, potency, and target specificity, as potential antifungal antimicrobials with activity against Pneumocystis species.
DISCUSSION
In the current study, we demonstrate that P. jirovecii contains a functional Rtt109 orthologue with functions parallel to those exhibited by PcRtt109, which is an important early characterization step in the drug discovery process. We first identified the putative PjRtt109 orthologue by using a recently published P. jirovecii genome. We then showed that a Pjrtt109-specific primer set specifically amplified a product of the expected size when P. jirovecii genomic DNA was used as the template but not when human genomic DNA was used, which demonstrates that this gene is contained within the P. jirovecii genome. Because P. jirovecii cannot be cultured in vitro, we utilized heterologous expression to show that Pjrtt109 restores genotoxin resistance and H3K56ac in rtt109-null yeast, which demonstrates its functional importance as an Rtt109 HAT in this surrogate in vivo system. We were further able to synthesize full-length Pjrtt109 cDNA to study the function of recombinantly expressed PcRtt109 protein.
We verified that PjRtt109 has HAT activity in vitro, comparable to that of its orthologue PcRtt109 and another fungal Rtt109, namely, SpRtt109. As in previous reports describing PcRtt109, the HAT activity of PjRtt109 was enhanced by the addition of the yeast histone chaperone Asf1, a salient feature of the well-characterized Rtt109-Vps75-Asf1 system in yeast. Finally, since small-molecule inhibition of Rtt109-catalyzed histone acetylation is hypothesized to be a potential novel epigenetically based antifungal therapy, we showed that the reported HAT inhibitors garcinol and compound 1 can inhibit PjRtt109 activity in vitro and these compounds inhibited PcRtt109 and PjRtt109 HAT activity comparably in vitro. Interestingly, garcinol, but not compound 1, also suppressed the viability of Pneumocystis organisms maintained ex vivo in viability medium.
Our observation that garcinol inhibits PjRtt109 and PcRtt109 as well as other HATs raises interesting follow-up questions about the target specificity of this natural product, its mechanism(s) of enzymatic inhibition, and its utility for additional in vivo studies. Garcinol has been reported to inhibit Pneumocystis and yeast Rtt109, as well as the HATs p300, PCAF, and GCN5, at low micromolar concentrations in vitro. It has also been reported to inhibit completely unrelated enzymes in vitro (71) . This behavior may be explained by the chemical structure of garcinol, which contains an orthocatechol group that has the potential to oxidize to form a thiol- carinii organisms were maintained ex vivo for 72 h in test medium, and organism viability was determined by relative ATP contents. Ampicillin (10 g/ml) and pentamidine (1 l/ml) were included as relevant negative-and positivecontrol compounds. The reported pan-HAT inhibitor garcinol exhibited a significant dose-dependent reduction in P. carinii viability. In contrast, the recently described Rtt109 inhibitor compound 1 failed to alter P. carinii viability under the conditions tested. A DMSO diluent control was also used. Shown are the results of three independent experiments. ‫,ء‬ P Ͻ 0.05, compared with control ATP levels without test agent.
reactive ortho-quinone (72) . Being aware of this possibility, we have so far been unable to detect the presence of glutathionegarcinol adducts by UPLC-MS, although we admit that this does not definitively exclude the possible formation of these adducts (data not shown). Garcinol also can induce apoptosis, inhibit cancer cell growth, and modulate several important signaling pathways and has been shown to exert some protective effects (73) (74) (75) (76) (77) (78) . With regard to potential mammalian toxicity, garcinol has been studied in several animal experiments, in which it showed certain chemoprotective effects and was relatively well-tolerated by rodents (79) (80) (81) . The overall in vitro data are consistent with garcinol being a relatively nonselective inhibitor, and this property may coincide with its ability to inhibit cancer cell growth in vitro. Given its in vitro activity profile and the relatively high concentrations used in our fungal viability assays, we cannot exclude the possibility of off-target effects contributing to the reduced viability of Pneumocystis upon exposure to garcinol. Therefore, we think that garcinol is not ideal for further in vivo experiments in its present form, because of its potential for off-target effects and the need for more-definitive mechanistic studies. More specific and potent chemical probes for HATs like Pneumocystis Rtt109 would be useful to better assess our therapeutic hypothesis in a cellular setting.
This demonstration that both PjRtt109 and PcRtt109 are functional HAT orthologues is significant for early Rtt109 drug discovery efforts for several reasons. First, it demonstrates that functional Rtt109 HATs are conserved across fungi. Second, it verifies that, in the absence of P. jirovecii culture systems, P. carinii may serve as an entirely suitable surrogate model for studying the Rtt109 system in the laboratory setting. In addition, the observation that reported small-molecule HAT inhibitors can disrupt PjRtt109 activity in vitro suggests that inhibitors developed for one species of Rtt109 may inhibit homologues across a variety of other fungal species, indicating that such a strategy may benefit a wide range of fungal infections. The discovery and development of more-potent small molecules targeting Rtt109 HATs will be useful to more rigorously address this speculation. Finally, our findings support further target characterization and drug development efforts with respect to PjRtt109, a potential epigenetic therapeutic target with clinical relevance as the specific cause of human PcP.
This study strongly validates the use of the P. carinii system for preclinical work of relevance for drug development eventually targeting human disease caused by P. jirovecii. We recently characterized the Rtt109-Vps75-Asf1 system in P. carinii, showing that PcRtt109 restores genotoxic resistance and H3K56ac levels in rtt109-null yeast. This system verifies many of the features found in the well-characterized S. cerevisiae and S. pombe Rtt109-Vps75-Asf1 systems in vitro, such as HAT activity being enhanced by the histone chaperone Asf1. As Rtt109 is conserved in fungi but not in mammals, specific inhibitors of Rtt109-catalyzed histone acetylation may eventually prove useful as novel antifungal targets across a number of relevant infections, including P. jirovecii-related pneumonia.
It is noteworthy that the general HAT inhibitor garcinol also reduced the in vitro viability of Pneumocystis organisms. Interestingly, the recently reported specific Rtt109 inhibitor compound 1 did not exhibit any suppression of Pneumocystis viability. Similar findings were noted when this compound was tested previously against C. albicans (43) . There are several possible reasons for our observations, including possibly poor penetration of compound 1 into the fungal cytoplasm, the presence of active rapid export proteins that may limit internal accumulation of this agent, or compound instability under the testing conditions. Nonetheless, the wide presence of Rtt109 proteins across pathogenic fungi, the divergence from mammalian host HAT proteins, and our initial results on such agents reducing Pneumocystis viability continue to support additional searches for more-selective anti-Rtt109 agents that may be of therapeutic benefit for fungal infections in humans, including P. jirovecii pneumonia.
